Talc Cancer Lawsuits Set To Convene
April 10, 2017 – – Talc powder litigation is scheduled to convene an additional two ovarian cancer trials in the next few months. The trials are part of the 22nd Circuit Court in St. Louis, Missouri, and the fifth trial is scheduled to begin on April 10, according to a spokesperson from consumer information site www.talcumpowder.org.
The spokesperson said, “The lawsuits filed against the manufacturer of talcum powder came from women who claim they developed ovarian cancer after using talcum based products for feminine hygiene. These products were distributed and marketed by Johnson & Johnson.”
To date, more than 3,000 such cases have been filed against the Johnson & Johnson. Class action lawsuits have been filed in numerous cities across the nation with nearly 1,000 of these cases being tried in the court in Missouri. There were additional complaints filed in state courts in California, Delaware, and New Jersey.
“In just the past year alone,” continues the talcumpowder.org representative, “four trials have been convened in Missouri and Johnson & Johnson has won only one of those cases. The plaintiffs in the other cases were awarded millions in damages.”
The other three trials against Johnson & Johnson ended with awarded compensation and punitive damages of $70 million, $72 million, and $55 million, respectively. Plaintiffs who have filed lawsuits against the pharmaceutical company allege that the regular use of Shower-to-Shower and Baby Powder manufactured by Johnson & Johnson led to the development of ovarian cancer and state that the pharmaceutical company knew of the risks associated with using these products for a long term on the genital areas yet they marketed them anyway.
Claims state that Johnson & Johnson knew as early as the 1970’s that prolonged use of talc based products could lead to ovarian cancer. A study published at that time showed a strong link between the use of talc in the genital region and the development of cancer. Claims state that the pharmaceutical giant refused to acknowledge these warnings and put the public at risk by continuing to manufacture and market those products without providing the public with the appropriate safety warnings regarding the risks of cancer.
###
Contact Drug-Lawsuits.org:
info@drug-lawsuits.org
ReleaseID: 60016896